Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ATAI Life Sciences N.V. - Common Shares (NQ:ATAI)

4.505 -0.145 (-3.12%)
Streaming Delayed Price Updated: 10:36 AM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ATAI Life Sciences N.V. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
 
Via Benzinga
Invitae, CSX And Other Big Stocks Moving Higher In Friday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gained in today’s pre-market trading session. Mullen Automotive, Inc. (NASDAQ: MULN) shares jumped 30.2% to $0.1103 in... 
Via Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
 
Via Benzinga
After Falling 60% in 1 Year, Is Atai Life Sciences Stock Still a Buy?
Atai's stock is hurting, but its pipeline is still packed with promising programs. 
Via The Motley Fool
Cybin, Mind Medicine Among Top Psychedelic Movers Of Today
 
Via Benzinga
Why Atai Life Sciences Stock Stormed Higher This Week
The biotech's strong financial position may be attracting bargain buyers right now. 
Via The Motley Fool
Psychedelic Stock Gainers And Losers From April 18, 2023
 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 17, 2023
 
Via Benzinga
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules 
Via Benzinga
Atai Advances R-Ketamine Through Phase 1 Bridging Study, Update And Near-Term Expectations
Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) announced the dosing of the first subject in majority-owned subsidiary Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous 
Via Benzinga
ATAI Life Sciences, Seelos Therapeutics Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 13, 2023
 
Via Benzinga
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
From atai Life Sciences
Via GlobeNewswire
Psychedelic Stock Gainers And Losers From April 12, 2023
 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 11, 2023
 
Via Benzinga
Psyched: MDMA Therapy Advances With FDA, Alternatives For Alcohol Addiction, Prince Harry In The Spotlight And More
MDMA Therapy For PTSD Nearing Legalization In U.S. And Worldwide, MAPS Releases Promising Data 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 10, 2023
 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 7, 2023
 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 6, 2023
 
Via Benzinga
Compass Pathways, GH Research Among Top Psychedelic Movers Of Today
 
Via Benzinga
"Rags-To-Riches" Portfolio Down 8.6% In March; Now -3.9% YTD
The 
Via Talk Markets
Psychedelic Stock Gainers And Losers From April 4, 2023
 
Via Benzinga
Butterfly Network, APE Preferred Shares And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
 
Via Benzinga
Largest Psychedelic Stocks -3.4% In March
The munKNEE Psychedelic Drug Stocks Index was down 3.4% in March but is still +1.2% YTD. The best news is the continuing high price targets being set by analysts. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From March 31, 2023
 
Via Benzinga
Why Shares of Atai Life Sciences Rose Friday
The company's co-founder and chairman increased his position and explained why. 
Via The Motley Fool
Seelos Therapeutics, Mind Medicine Among Top Psychedelic Movers Of Today
 
Via Benzinga
IntelGenx's Q4 And Full-Year 2022 Financials, 'On The Cusp' Of Rapid Growth?
Drug delivery company IntelGenx Technologies Corp. (OTCQB: IGXT)’s financial results for the three and twelve months ended December 31, 2022 show: 
Via Benzinga
$1.6M Bet On ATAI Life Sciences? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones closed higher by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.